CLSI Guided Reference Interval Limits for Cancer Biomarkers for Adults and Geriatrics

Reference interval limits for cancer biomarkers in geriatrics are rare because priority is given to the development of reference those age range 18–60 years, which normally used clinical trials study. The aim this study was therefore develop gender and age-specific markers CA19-9, CEA, CA 15-3, 125, PSA adults Taita-Taveta County, Kenya, using CLSI CA28-A3 guideline. This prospective cross-sectional involved 244 healthy referents, including 124 females 120 males ages 50–95, between May 2015 December 2017 at Department Clinical Chemistry Moi Subcounty Hospital, Voi, Kenya. Serum 19-9, referents were measured a well-calibrated, quality controlled AutoAnalyzer. Gender differences values assessed Mann-Whitney U test, while Kruskal-Wallis H test followed by with an adjusted significant ρ-value less than 0.0167. expressed terms medians ranged 2.5 97.5 percentiles. established 95% were: 0-58 U/mL 0-42.8 19–9, 0–7 ng/mL 0-56.9 15–3, 0–25 0–6.8 PSA. Gender-related biomarker developed 19-9 (60–70 years), CEA 15-3 adults. Age-related 19–9 not females. In conclusion, gender-related PSA, age-related 19-9. decreased from adulthood early elderly increased more population. These these biomarkers, differed reported previous literature, could be adopted use better medical care. Doi: 10.28991/SciMedJ-2022-04-02-04 Full Text: PDF